Prandin and Osteolysis - a phase IV clinical study of FDA data

Summary:

Osteolysis is reported as a side effect among people who take Prandin (repaglinide), especially for people who are female, 50-59 old, also take Percocet, and have Osteoporosis.

The phase IV clinical study analyzes which people have Osteolysis when taking Prandin. It is created by eHealthMe based on reports of 4,613 people who have side effects when taking Prandin from the FDA, and is updated regularly.

What is Prandin?

Prandin has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 4,680 Prandin users. Check the latest studies of Prandin.

What is Osteolysis?

Osteolysis (dissolution of bone) is found to be associated with 688 drugs and 407 conditions by eHealthMe. Check the latest studies of Osteolysis.

On Jul, 06, 2026

4,613 people reported to have side effects when taking Prandin.
Among them, 43 people (0.93%) have Osteolysis.

Among these 43 people:

What is the gender of people who have Osteolysis when taking Prandin? *

female: 62.79 %
male: 37.21 %

What is the age of people who have Osteolysis when taking Prandin? *

What are other drugs people take besides Prandin? *

What are other side effects people have besides Osteolysis? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 43 people, 100.00%
Swelling: 43 people, 100.00%
Tooth Disorder (tooth disease): 42 people, 97.67%
Acute Kidney Failure: 42 people, 97.67%
Osteomyelitis (infection of bone): 42 people, 97.67%
Pain: 42 people, 97.67%
Bone Pain: 42 people, 97.67%
Sinusitis (inflammation of sinus): 40 people, 93.02%
Spinal Osteoarthritis (joint cartilage loss in spine): 39 people, 90.70%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 37 people, 86.05%

What are the existing conditions these people have? *

Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 27 people, 62.79%
Osteoporosis (bones weak and more likely to break): 27 people, 62.79%
Multiple Myeloma (cancer of the plasma cells): 14 people, 32.56%
Thrombocytopenia (decrease of platelets in blood): 11 people, 25.58%
Insomnia (sleeplessness): 3 people, 6.98%
Metastases To Bone (cancer spreads to bone): 2 people, 4.65%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 2.33%
Metastatic Neoplasm (spreadable cancer tumour): 1 person, 2.33%
Hypersensitivity: 1 person, 2.33%
Breast Cancer Metastatic: 1 person, 2.33%

* Approximation only. Some reports may have incomplete information.

Do you take Prandin and have Osteolysis?

- Check whether Osteolysis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Prandin:

Prandin (4,680 reports)

Osteolysis treatments and more:

Osteolysis (4,092 reports)

Browse all side effects of Prandin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteolysis:

Osteolysis (688 drugs)

Browse all the conditions that are associated with Osteolysis:

Osteolysis (407 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on repaglinide (the active ingredients of Prandin) and Prandin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.